Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acumen Pharmaceuticals, Inc.

1.23
+0.02001.65%
Post-market: 1.240.0100+0.81%16:41 EST
Volume:203.33K
Turnover:249.34K
Market Cap:73.90M
PE:-0.89
High:1.27
Open:1.19
Low:1.18
Close:1.21
Loading ...

Company Profile

Company Name:
Acumen Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
52
Office Location:
427 Park Street,Charlottesville,Virginia,United States
Zip Code:
22902
Fax:
- -
Introduction:
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Directors

Name
Position
Daniel O'Connell
President and Chief Executive Officer and Director
Jeffrey L. Ives
Director
Jeffrey Sevigny
Director
Laura Stoppel
Director
Nathan B. Fountain
Director
Sean Stalfort
Director

Shareholders

Name
Position
Daniel O'Connell
President and Chief Executive Officer and Director
Russell Barton
Chief Operating Officer
Matthew Zuga
Chief Financial Officer and Chief Business Officer
Eric Siemers
Chief Medical Officer